SHI Jing , YU Zixiang , MA Yitong , YANG Yining , MA Xiang , LI Xiaomei , LIU Fen
  • Heart Center, the First Affiliated Hospital of Xinjiang Medical University, Urumchi, 830054, P.R.China;
MA Yitong, Email: myt-xj@163.com
Drug-eluting stents; Antiplatelet therapy; Meta-analysis; Randomized controlled trial; Systematic review
10.7507/1672-2531.201610042
Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables References Cited by

Objective  To systematically review the efficacy and safety of different duration of dual antiplatelet therapies in patients undergoing new-generation drug-eluting stents implantation. Methods  Such databases as MEDLINE, The Cochrane Library (Issue 2, 2015), EMbase, CBM, CNKI and WanFang Data were searched to collect studies on the different duration of dual antiplatelet therapies in patients undergoing new-generation drug-eluting stents implantation from inception to April 2015. Two reviewers independently screened literature, extracted data and assessed the risk of bias of included studies. Then, meta-analysis was performed using RevMan 5.3 software. Results  Six trials were included. The results of meta-analysis showed: compared with 12 months dual antiplatelet therapy group, the incidence of bleeding in the 6 months dual antiplatelet therapy group was lower (OR=0.48, 95%CI 0.26 to 0.89, P=0.02). There were no significant differences in incidence of myocardial infarction, all cause mortality, stroke and stent thrombosis between two groups. Compared with 24 months dual antiplatelet therapy group, the incidence of stent thrombosis in the 12 months dual antiplatelet therapy group was higher (OR=2.50, 95%CI 1.13 to 5.61, P=0.02), but the incidence of bleeding in 12 months dual antiplatelet therapy group was lower (OR=0.25, 95%CI 0.07 to 0.89, P=0.03). No significant differences were found in the incidence of myocardial infarction, all cause mortality and stroke between 12 months dual antiplatelet therapy group and 24 months dual antiplatelet therapy group. Conclusions  6 months dual antiplatelet therapy following new-generation drug-eluting stent implantation is relatively more safe and efficacy. There is significant increase of incidence of bleeding in 12 or 24 months dual antiplatelet therapy. Due to the limited quantity and quality of included studies, the above results are needed to be validated by more high quality studies.

Citation： SHI Jing, YU Zixiang, MA Yitong, YANG Yining, MA Xiang, LI Xiaomei, LIU Fen. Efficacy and safety of different duration of dual antiplatelet therapy in patients undergoing new-generation drug-eluting stents implantation: a meta-analysis. Chinese Journal of Evidence-Based Medicine, 2017, 17(8): 959-963. doi: 10.7507/1672-2531.201610042 Copy

  • Previous Article

    The influence of different operation to pulmonary function in patients with early stage non-small cell lung cancer: a meta-analysis

  • Next Article

    Efficacy of zoledronic acid on postoperative osteoporosis vertebral fracture patients undergoing percutaneous vertebroplasty or percutaneous kyphoplasty: a meta-analysis